Navigation Links
Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies
Date:11/9/2009

uated participants' signs and symptoms of ADHD on a once-weekly basis using the clinician administered and scored ADHD Rating Scale-IV (ADHD-RS-IV), a scale frequently used in ADHD clinical trials that assesses hyperactive, impulsive, and inattentive symptoms. The primary outcome was the change in total ADHD-RS-IV scores from baseline to end point in both studies.

Both trials demonstrated statistically significant improvements in ADHD-RS-IV scores in patients taking INTUNIV beginning one to two weeks after patients began receiving once-daily doses of INTUNIV. In the first pivotal trial, the mean reduction in ADHD-RS-IV total scores at end point were -16.7 for INTUNIV compared to -8.9 for placebo (P< .0001); the mean reduction in ADHD-RS-IV total scores in the second pivotal trial were -19.6 for INTUNIV and -12.2 for placebo (P=.0040). Placebo-adjusted LS mean changes from baseline were statistically significant for all INTUNIV doses in the randomized treatment groups in both studies.

Additional secondary efficacy outcome measures included the Conners' Parent Rating Scale-Revised: Short Form (CPRS-R) and the Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R). CPRS-R and CTRS-R are comprehensive scales that use parent and teacher observer and self-report ratings to help assess ADHD symptoms and behaviors in children and adolescents. Among some of the symptoms measured were: inattentiveness/being easily distracted, running around or climbing excessively, arguing with adults, losing temper, and interrupting or intruding on others. Significant improvements in mean day total scores were seen on both scales: based on the CPRS-R, parents reported significant improvement across a full day (as measured at 6 PM, 8 PM, and 6 AM the next morning); based on the CTRS-R, which was used only in the first pivotal trial, teachers reported significant improvement throughout the school day (as measured at 10 AM and 2 PM).

Safety was also
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
2. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
3. Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
4. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
5. Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
6. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
7. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
8. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
9. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
10. Once-Daily Combo Works for New HIV Patients
11. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 SAN DIEGO, ... Gulfport Mississippi, is the first healthcare provider along ... to chronic care management (CCM). In partnership with ... is introducing RevUp, a new program that enables ... and increase monthly reimbursements. This new, user-friendly program ...
(Date:5/27/2015)... HOUSTON, Tx (PRWEB) May 27, 2015 ... combined germline pharmacogenomic and somatic genomic analysis in personalized ... was published by the American Society of Clinical Oncology ... – June 2 in Chicago. , The molecular and ... The Cancer Genome Atlas (TCGA) database. The study reports ...
(Date:5/27/2015)... On June 5, Plan B [the agency alternative], ... to host Donate Your Break, a public blood drive. ... donor coach outside of 116 W. Illinois (at LaSalle) ... whole blood units is highest for LifeSource, the largest ... requires approximately 1,000 donations per day to maintain an ...
(Date:5/27/2015)... 2015 This is a professional ... the Omega-3 industry. The report provides a basic ... and industry chain structure. The Omega-3 market analysis ... trends, competitive landscape analysis, and key regions development ... Fishing Company, Seadragon Marine Oils, Norwegian Fish Oil, ...
(Date:5/27/2015)... 2015 SonarMD, LLC, recently ... a first-of-its kind, cloud-based algorithmic process for ... chronic gastrointestinal disease. , Developed by noted ... allows physicians to monitor their patients’ health ... of electronic health assessment surveys. Using nationally ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... Roger Seaver, president and CEO of Henry Mayo ... the Hospital Association of Southern California (HASC) for ... leading the board in developing public policies to ... and enhancing communication and consensus on public policy ...
... (UC) researchers have discovered that estrogen receptors are ... brain tumorleading them to believe that anti-estrogen drug ... and improving patients, overall outcome. , This research ... of Endocrinology . , In estrogen-responsive cancerssuch ...
... Marmot, chair of the World Health Organization Commission ... the International Institute for Society and Health at ... Health Lecture Series talk, "Social Determinants of Health: ... Lecture Series is organized by Martin Seligman, University ...
... 17 The Quantum Group, Inc. (NYSE Amex: ... PWeR(TM) (Personal Wellness electronic Record) demonstrations presented at the ... standing room only crowds throughout the 3-day event.Pete Martinez, ... Officer, led the team responsible for the development of ...
... Cross rolls out red carpet for one of its ... the most watched awards show on television, the American ... Barnes, Executive Director of the West Alabama Chapter in ... years ago in Vicksburg (MS). During his tenure with ...
... research? The National Institutes of Health (NIH) wants to ... March 4-6 on behalf of the NIH Office of ... research priorities for the next decade. The meeting begins ... health-care providers, patients, community groups, advocacy groups and other ...
Cached Medicine News:Health News:Henry Mayo CEO Elected Chairman of Hospital Association of Southern California 2Health News:Estrogen found to increase growth of the most common childhood brain tumor 2Health News:The Quantum Group Announces Standing-Room-Only PWeR(TM) Demonstrations at Pri-Med South Expo 2Health News:The Quantum Group Announces Standing-Room-Only PWeR(TM) Demonstrations at Pri-Med South Expo 3Health News:American Red Cross: Meet Our Oscar! 2Health News:American Red Cross: Meet Our Oscar! 3Health News:American Red Cross: Meet Our Oscar! 4Health News:WU hosts public hearing, conference to help NIH prioritize women's health research 2
(Date:5/27/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... updated its full year 2015 financial guidance and business ... Updated Financial Guidance , Total revenues for ... expected to be between $7.0 and $8.0 million. The Company ... for the remainder of the year, and therefore expects ...
(Date:5/27/2015)... , May 27, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... a member of the Roche Group, announced today a ... for Ventana to ultimately commercialize, a companion diagnostic assay ... The Ventana assay will be used to ... – a chain of natural sugars distributed throughout human ...
(Date:5/27/2015)... 27, 2015 Encision Inc. (OTCQB:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... fiscal year ended March 31, 2015. The ... a quarterly net loss of $349 thousand, or $(0.03) ... $2.504 million for a net loss of $1.453 million, ...
Breaking Medicine Technology:IGI Laboratories Updates Business Outlook 2IGI Laboratories Updates Business Outlook 3Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 2Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 3Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 4Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 5Encision Reports Fourth Quarter And Fiscal Year 2015 Results 2Encision Reports Fourth Quarter And Fiscal Year 2015 Results 3Encision Reports Fourth Quarter And Fiscal Year 2015 Results 4Encision Reports Fourth Quarter And Fiscal Year 2015 Results 5Encision Reports Fourth Quarter And Fiscal Year 2015 Results 6
... 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... clinical and preclinical data highlighting the safety and efficacy ... New Phase 3 data on the ... after augmentation mammoplasty will be presented by Sergio Bergese, ...
... 5, 2011 Xlumena, Inc., a ... endoscopist and endoscopic surgeon, announced today that it ... AXIOS™ Stent and Delivery System (AXIOS). The AXIOS ... translumenal therapy and is indicated for drainage of ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations 5Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: